RefleXion Medical is a biotargeting oncology company that combines medical physics, nuclear medicine, and radiotherapy to shift the paradigm of cancer care. Their innovative SCINTIX Therapy, now FDA cleared, utilizes biology-guided radiotherapy to detect and respond to signals emitted from cancer, enabling immediate treatment for lung or bone tumors. RefleXion aims to reveal cancer like never before and create a machine that combines biotargeting with radiation for systemic reach in radiotherapy, benefiting patients at any stage of cancer. The company has raised significant funding and received recognition for its breakthrough technology in localized cancer treatment.